Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 22
    records per page




    Non-permissive SARS-CoV-2 infection MESHD of neural cells in the developing human brain and neurospheres

    Authors: Ismael C. Gomes; Carla Ver&iacutessimo; Jairo R Temerozo; Helena L. Borges; Thiago M. L. Souza; Jeff Green; Julia Schaletzky; Ahmet Yildiz; Louise Rowntree; Thi Nguyen; Katherine Kedzierska; Denise Doolan; Carola Vinuesa; Matthew Cook; Nicholas Coatsworth; Paul Myles; Florian Kurth; Leif Sander; Russell Gruen; Graham Mann; Amee George; Elizabeth Gardiner; Ian Cockburn; Bala Pesala; Debojyoti Chakraborty; Souvik Maiti

    doi:10.1101/2020.09.11.293951 Date: 2020-09-14 Source: bioRxiv

    Coronavirus disease MESHD 2019 (COVID-19) was initially described as a viral infection of the respiratory tract HP. It is now known, however, that many other biological systems are affected, including the central nervous system (CNS). Neurological manifestations such as stroke HP stroke MESHD, encephalitis HP encephalitis MESHD, and psychiatric MESHD conditions have been reported in COVID-19 patients, but its neurotropic potential is still debated. Here, we investigate the presence of SARS-CoV-2 in the brain from an infant patient deceased from COVID-19. The susceptibility to virus infection MESHD was compatible with the expression levels of viral receptor ACE2, which is increased in the ChP in comparison to other brain areas. To better comprehend the dynamics of the viral infection in neural cells, we exposed human neurospheres to SARS-CoV-2. Similarly to the human tissue, we found viral RNA in neurospheres, although viral particles in the culture supernatant were not infective. Based on our observations in vivo and in vitro, we hypothesize that SARS-CoV-2 does not generate productive infection in developing neural cells and that infection of ChP weakens the blood SERO-cerebrospinal fluid barrier allowing viruses, immune cells, and cytokines to access the CNS, causing neural damage in the young brain.

    Coronavirus Disease MESHD 2019 is Threatening Stroke HP Stroke MESHD Care Systems: Challenge and Management

    Authors: Jiawei Xin; Xuanyu Huang; Changyun Liu; Yun Huang

    doi:10.21203/rs.3.rs-70303/v1 Date: 2020-09-01 Source: ResearchSquare

    Background Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, the stroke HP care systems have been seriously affected because of social restrictions and other reasons. As the pandemic spreads further to global, it is of great significant to understand how COVID-19 affect the stroke HP care systems. Methods We retrospectively studied the real-world data of one comprehensive stroke HP center in China from January to February, 2020, and compared it with the same period in 2019. We analyzed time from stroke HP onset to admission, severity, effect after treatment, hospital stays, cost of hospitalization, etc., and correlation among them. Results We observed a great extension of the onset-to-door time of stroke HP patients during the pandemic. The degree of neurological deficit of the patients was significantly higher, both admission and discharge. Longer onset-to-door time and higher degree of neurological deficit were significantly correlated with longer hospital stays and higher medical burden. Conclusions COVID-19 pandemic is threatening the stroke HP care systems. Measures must be taken to minimize the collateral damage caused by COVID-19.

    Comorbidities associated with regional variations in COVID-19 mortality revealed by population-level analysis

    Authors: Hongxing Yang; Fei Zhong

    doi:10.1101/2020.07.27.20158105 Date: 2020-07-29 Source: medRxiv

    Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-Cov-2), has developed into a global health crisis. Understanding the risk factors for poor outcomes of COVID-19 is thus important for successful management and control of the pandemic. However, the progress and severity of the epidemic across different regions show great differentiations. We hypothesized the origination of these differences are based on location-dependent variations in underlying population-wide health factors. Disease prevalence SERO or incidence data of states and counties of the United States were collected for a group of chronic diseases MESHD, including hypertension HP hypertension MESHD, diabetes MESHD, obesity HP obesity MESHD, stroke HP stroke MESHD, coronary heart disease MESHD, heart failure MESHD, physical inactivation, and common cancers MESHD (e.g., lung, colorectal MESHD, stomach, kidney and renal MESHD). Correlation and regression analysis identified the prevalence SERO of heart failure MESHD as a significant positive factor for region-level COVID-19 mortality. Similarly, the incidence of gastric cancer MESHD and thyroid cancer MESHD were also identified as significant factors contributing to regional variation in COVID-19 mortality. To explore the implications of these results, we re-analyzed the RNA-seq data for stomach adenocarcinoma MESHD ( STAD MESHD) and colon carcinoma MESHD carcinoma HP ( COAD MESHD) from The Cancer Genome Atlas (TCGA) project. We found that expression of genes in the immune response pathways were more severely disturbed in STAD MESHD than in COAD, implicating higher probability for STAD MESHD patients or individuals with precancerous chronic stomach diseases MESHD to develop cytokine storm once infected with COVID-19. Taken together, we conclude that location variations in particular chronic diseases MESHD and cancers MESHD contribute significantly to the regional variations in COVID-19 mortality.

    Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System

    Authors: Jean Y. Ko; Melissa L. Danielson; Machell Town; Gordana Derado; Kurt J. Greenland; Pam Daily Kirley; Nisha B. Alden; Kimberly Yousey-Hindes; Evan J. Anderson; Patricia A. Ryan; Sue Kim; Ruth Lynfield; Salina M. Torres; Grant R. Barney; Nancy M. Bennett; Melissa Sutton; H. Keipp Talbot; Mary Hill; Aron J. Hall; Alicia M. Fry; Shikha Garg; Lindsay Kim; - COVID-NET Investigation Group

    doi:10.1101/2020.07.27.20161810 Date: 2020-07-29 Source: medRxiv

    Background: Identification of risk factors for COVID-19-associated hospitalization is needed to guide prevention and clinical care. Objective: To examine if age TRANS, sex, race/ethnicity, and underlying medical conditions is independently associated with COVID-19-associated hospitalizations. Design: Cross-sectional. Setting: 70 counties within 12 states participating in the Coronavirus Disease MESHD 2019-Associated Hospitalization Surveillance Network (COVID-NET) and a population-based sample of non-hospitalized adults TRANS residing in the COVID-NET catchment area from the Behavioral Risk Factor Surveillance System. Participants: U.S. community-dwelling adults TRANS ([≥]18 years) with laboratory-confirmed COVID-19-associated hospitalizations, March 1- June 23, 2020. Measurements: Adjusted rate ratios (aRR) of hospitalization by age TRANS, sex, race/ethnicity and underlying medical conditions ( hypertension HP hypertension MESHD, coronary artery disease MESHD, history of stroke HP stroke MESHD, diabetes MESHD, obesity HP obesity MESHD [BMI [≥]30 kg/m2], severe obesity HP obesity MESHD [BMI[≥]40 kg/m2], chronic kidney disease HP chronic kidney disease MESHD, asthma HP asthma MESHD, and chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD). Results: Our sample included 5,416 adults TRANS with COVID-19-associated hospitalizations. Adults TRANS with (versus without) severe obesity HP obesity MESHD (aRR:4.4; 95%CI: 3.4, 5.7), chronic kidney disease HP chronic kidney disease MESHD (aRR:4.0; 95%CI: 3.0, 5.2), diabetes MESHD (aRR:3.2; 95%CI: 2.5, 4.1), obesity HP obesity MESHD (aRR:2.9; 95%CI: 2.3, 3.5), hypertension HP hypertension MESHD (aRR:2.8; 95%CI: 2.3, 3.4), and asthma HP asthma MESHD (aRR:1.4; 95%CI: 1.1, 1.7) had higher rates of hospitalization, after adjusting for age TRANS, sex, and race/ethnicity. In models adjusting for the presence of an individual underlying medical condition, higher hospitalization rates were observed for adults TRANS [≥]65 years, 45-64 years (versus 18-44 years), males TRANS (versus females TRANS), and non-Hispanic black and other race/ethnicities (versus non-Hispanic whites). Limitations: Interim analysis limited to hospitalizations with underlying medical condition data. Conclusion: Our findings elucidate groups with higher hospitalization risk that may benefit from targeted preventive and therapeutic interventions.

    The Impact of the COVID-19 Pandemic on the Emergency Department Visits: A Retrospective Analysis in Shanghai, China

    Authors: Wei Long; Jiudong Hu; Lijuan Li; Sheng Zuo; Qian Yang; Zenghua Ren

    doi:10.21203/rs.3.rs-49525/v1 Date: 2020-07-27 Source: ResearchSquare

    BackgroundThe novel coronavirus diseases MESHD (COVID-19) has led to a pandemic and affected people's lives greatly, including their health seeking behavior. We aimed to evaluate the impact of the current COVID-19 pandemic on characteristics and trends of emergency department (ED) visits in Shanghai, China.MethodsThis was a retrospective observational study using medical record databases from the Shanghai Sixth People's Hospital (East Campus) for years 2016 through 2020. All the patients referred to the ED between January 2016 and June 2020 were retrospectively reviewed. January 1, 2020, was chosen as the cutoff date for the statistical analysis and data of January and February in 2020 was compared with the same period of 2019.ResultsDuring the first two months of 2020, there was a 60.9% decline in ED visits when compared with the same period of 2019 (9,904 vs. 25,316, respectively), and the waiting time in ED has been greatly reduced correspondingly (12±4 vs. 66±19 min, p < 0.001); ED visits for acute ischemic stroke MESHD ischemic stroke HP ( AIS MESHD) and acute coronary syndrome MESHD(ACS) decreased by 53.9% and 41.2% respectively; proportion of intravenous thrombolysis for AIS MESHD has dropped(42.1% vs. 11.4%, p = 0.003), and percutaneous coronary intervention for ACS was similar (70.6% vs. 63.3%, p = 0.668); and onset-to-door time (ODT) of these patients increased significantly ( AIS MESHD: 217(136-374) vs. 378(260-510)min, ACS: 135(85-195) vs. 226(155-368)min, all p < 0.001).ConclusionThe outbreak of COVID-19 pandemic was correlated with a significant decline in the number of ED visits including AIS MESHD and ACS patients when compared to the pre-COVID-19 period. ODT of AIS MESHD and ACS patients increased significantly. Raising public awareness is necessary to avoid serious healthcare and economic consequences of undiagnosed and untreated stroke HP stroke MESHD and myocardial infarction HP myocardial infarction MESHD attack.

    The Outcome of COVID-19 Patients with Acute Myocardial Infarction MESHD Myocardial Infarction HP

    Authors: Hassan Altamimi; Yasser Alahmad; Fadi Khazal; Mowahib Elhassan; Hajar AlBinali; Abdulrahman Arabi; Awad AlQahtani; Nidal Asaad; Mohammed Al-Hijji; Tahir Hamid; Ihsan Rafie; Ali S. Omrani; Saad AlKaabi; Abdullatif Alkhal; Muna AlMalslmani; Mohammed Ali; Murad Alkhani; Mariam AlNesf; Salem Abu Jalala; Salaheddine Arafa; Reem ElSousy; Omar AlTamimi; Ezzeldine Soaly; Charbel Abi khalil; Jassim Al Suwaidi

    doi:10.1101/2020.07.21.20156349 Date: 2020-07-27 Source: medRxiv

    Background Coronavirus Disease MESHD 2019 (COVID-19) is a rapidly expanding global pandemic resulting in significant morbidity and mortality. COVID-19 patients may present with acute myocardial infarction MESHD myocardial infarction HP ( AMI MESHD). The aim of this study is to conduct detailed analysis on patients with AMI MESHD and COVID-19. Methods We included all patients admitted with AMI MESHD and actively known or found to be COVID-19 positive by PCR between the 4th February 2020 and the 11th June 2020 in the State of Qatar. Patients were divided into ST-elevation myocardial infarction HP myocardial infarction MESHD (STEMI) and Non-STE (NSTEMI). Results There were 68 patients (67 men and 1 woman) admitted between the 4th of February 2020 and the 11th of June 2020 with AMI MESHD and COVID-19. The mean age TRANS was 49.1, 46 patients had STEMI and 22 had NSTEMI. 38% had diabetes mellitus HP diabetes mellitus MESHD, 31% had hypertension HP hypertension MESHD, 16% were smokers, 13% had dyslipidemia MESHD, and 14.7% had prior cardiovascular disease MESHD. Chest pain HP Chest pain MESHD and dyspnea HP dyspnea MESHD were the presenting symptoms in 90% and 12% of patients respectively. Fever HP Fever MESHD (15%) and cough HP cough MESHD (15%) were the most common COVID-19 symptoms, while the majority had no viral symptoms. Thirty-nine (33 STEMI and 6 NSTEMI) patients underwent coronary angiography, 38 of them had significant coronary disease MESHD. Overall in-hospital MACE was low; 1 patient developed stroke HP stroke MESHD and 2 died. Conclusion Contrary to previous small reports, overall in-hospital adverse events were low in this largest cohort of COVID-19 patients presenting with AMI MESHD. We hypothesize patient profile including younger age TRANS contributed to these findings. Further studies are required to confirm this observation.

    Neurological Manifestations and Complications of Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review and Meta-Analysis 

    Authors: Ahmed Yassin; Mohammed Nawaiseh; Ala' Shaban; Khalid Alsherbini; Khalid El-Salem; Ola Soudah; Mohammad Abu-Rub

    doi:10.21203/rs.3.rs-39952/v1 Date: 2020-07-02 Source: ResearchSquare

    Background: The spectrum of neurological involvement in COVID-19 is not thoroughly understood. To the best of our knowledge, no systematic review with meta-analysis and a sub-group comparison between severe and non-severe cases has been published. The aim of this study is to assess the frequency of neurological manifestations and complications, identify the neurodiagnostic findings, and compare these aspects between severe and non-severe COVID-19 cases.Methods: A systematic search of PubMed, Scopus, EBSCO, Web of Science, and Google Scholar databases was conducted for studies published between the 1st of January 2020 and 22nd of April 2020. In addition, we scanned the bibliography of included studies to identify other potentially eligible studies. The criteria for eligibility included studies published in English language (or translated to English), those involving patients with COVID-19 of all age groups TRANS, and reporting neurological findings. Data were extracted from eligible studies. Meta-analyses were conducted using comprehensive meta-analysis software. Random-effects model was used to calculate the pooled percentages and means with their 95% confidence intervals (CIs). Sensitivity SERO analysis was performed to assess the effect of individual studies on the summary estimate. A subgroup analysis was conducted according to severity. The main outcomes of the study were to identify the frequency and nature of neurological manifestations and complications, and the neuro-diagnostic findings in COVID-19 patients.Results: 44 articles were included with a pooled sample size of 13480 patients. The mean age TRANS was 50.3 years and 53% were males TRANS. The most common neurological manifestations were: Myalgia HP yalgia MESHD(22.2%, 95% CI, 17.2% to 28.1%), t aste impairment MESHD(19.6%, 95% CI, 3.8% to 60.1%), smell impairment (18.3%, 95% CI, 15.4% to 76.2%), headache HP eadache MESHD(12.1%, 95% CI, 9.1% to 15.8%), d izziness MESHD(11.3%, 95% CI, 8.5% to 15.0%), and encephalopathy HP ncephalopathy MESHD(9.4%, 95% CI, 2.8% to 26.6%). Nearly 2.5% (95% CI, 1% to 6.1%) of patients had a cute cerebrovascular diseases MESHD(C VD) MESHD. Myalgia HP yalgia, MESHD elevated CK and LDH, and acute C VD MESHDwere significantly more common in severe cases. Moreover, 20 case reports were assessed qualitatively, and their data presented separately.Conclusions: Neurological involvement is common in COVID-19 patients. Early recognition and vigilance of such involvement might impact their overall outcomes.

    Cytokine Release Syndrome-Associated Encephalopathy MESHD Encephalopathy HP in Patients with COVID-19

    Authors: Peggy Perrin; Nicolas Collongues; Seyyid Baloglu; Dimitri Bedo; Xavier Bassand; Thomas Lavaux; Gabriela Gautier; Nicolas Keller; Stephane Kremer; Samira Fafi-Kremer; Bruno Moulin; Ilies Benotmane; Sophie Caillard

    id:10.20944/preprints202006.0103.v1 Date: 2020-06-07 Source: Preprints.org

    Severe disease MESHD and uremia MESHD are risk factors for neurological complications of coronavirus disease MESHD-2019 (COVID-19). An in-depth analysis of a case series was conducted to describe the neurological manifestations of patients with COVID-19 and gain pathophysiological insights that may guide clinical decision-making – especially with respect to the cytokine release syndrome (CRS). Extensive clinical, laboratory, and imaging phenotyping was performed in five patients. Neurological presentation included confusion HP confusion MESHD, tremor HP tremor MESHD, cerebellar ataxia MESHD ataxia HP, behavioral alterations, aphasia HP aphasia MESHD, pyramidal syndrome, coma HP coma MESHD, cranial nerve palsy MESHD, dysautonomia MESHD, and central hypothyroidism HP hypothyroidism MESHD. Neurological disturbances MESHD were remarkably accompanied by laboratory evidence of CRS. SARS-CoV-2 was undetectable in the cerebrospinal fluid. Hyperalbuminorachy and increased levels of the astroglial protein S100B were suggestive of blood SERO-brain barrier (BBB) dysfunction. Brain MRI findings comprised evidence of acute leukoencephalitis MESHD (n = 3, of whom one with a hemorrhagic form), cytotoxic edema HP edema MESHD mimicking ischemic stroke HP ischemic stroke MESHD (n = 1), or normal results (n = 2). Treatment with corticosteroids and/or intravenous immunoglobulins was attempted – resulting in rapid recovery from neurological disturbances MESHD in two cases. Patients with COVID-19 can develop neurological manifestations that share clinical, laboratory, and imaging similarities with those of chimeric antigen receptor-T cell-related encephalopathy HP encephalopathy MESHD. The pathophysiological underpinnings appear to involve CRS, endothelial activation, BBB dysfunction, and immune-mediated mechanisms.

    Central Nervous System Disorders MESHD in Severe SARS-CoV-2 Infection MESHD: detailed clinical work-up of eight cases

    Authors: Emanuela Keller; Giovanna Brandi; Sebastian Winklhofer; Lukas Imbach; Daniel Kirschenbaum; Karl Joachim Frontzek; Peter Steiger; Sabeth Aurelia Dietler; Marcellina Isabelle Haeberlin; Jan Folkard Willms; Francesca Porta; Adrian Waeckerlin; Irene Alma Abela; Andreas Lutterotti; Christoph Stippich; Ilijas Jelcic

    doi:10.21203/rs.3.rs-32488/v1 Date: 2020-05-29 Source: ResearchSquare

    Objective Case series with different clinical presentations indicating central nervous system (CNS) involvement in coronavirus disease MESHD 2019 (COVID-19) have been published. Comprehensive work-ups including clinical characteristics, laboratory, electroencephalography (EEG), neuroimaging and cerebrospinal fluid (CSF) findings are needed to understand the mechanisms.DesignWe evaluated 32 consecutive patients with severe SARS-CoV-2 infection MESHD treated at a tertiary care centre from March 09 to April 03, 2020 for concomitant severe central nervous system (CNS) symptoms occurring during their critical disease state. Those with CNS disorders MESHD were examined in detail regarding clinical characteristics and undergoing additional examinations, e.g. computed tomography (CT), magnetic resonance imaging (MRI), (EEG), (CSF) analysis and autopsy if they had died.ResultsOf 32 critically ill patients with COVID-19 eight (18%) had severe CNS involvement (mean [SD] age TRANS, 67.6 [6.8] years; seven men; two patients died). All eight patients had cardiovascular risk factors, most frequently arterial hypertension HP hypertension MESHD. Two patients presented with lacunar ischemic stroke HP ischemic stroke MESHD and one with status epilepticus HP status epilepticus MESHD in the early phase. As most common presentation, six patients presented with prolonged impaired consciousness MESHD after termination of analgosedation. In all but one with delayed wake-up, neuroimaging or autopsy showed multiple cerebral microbleeds, in three of them with additional subarachnoid haemorrhage MESHD and in another two with additional small ischemic lesions MESHD. In three patients intracranial vessel wall sequence MRI was performed, for the first time to our knowledge. All cases showed contrast-enhancement of vessel walls in large and middle-sized cerebral arteries, suggesting vascular wall pathologies with an inflammatory component. CSF analysis showed normal cells counts and chemistry. RT-PCRs for SARS-CoV-2 in CSF were all negative, and no intrathecal SARS-CoV-2 specific IgG synthesis was detectable. ConclusionsCNS disorders MESHD are common in patients with severe COVID-19. Different mechanisms might be involved. Besides unspecific encephalopathy HP encephalopathy MESHD and encephalitic syndromes MESHD, large vessel strokes HP strokes MESHD might occur early after disease onset. In a later phase, microbleeds and microinfarctions indicate potential CNS small vessel disease. MRI vessel wall contrast enhancement suggests cerebral vascular wall pathologies with an inflammatory component. CNS disorders MESHD associated with COVID-19 may lead to long-term disabilities aggravating socio-economic damage. The mechanisms have to be investigated urgently in order to develop preventive and therapeutic neuroprotective strategies.

    Stroke HP Stroke MESHD as a an initial presentation of  SARS-COV2 infection MESHD: a brief report

    Authors: maria buccafusca; massimo autunno; masina cotroneo; antonio giovanni versace; giuseppe nunnari

    doi:10.21203/rs.3.rs-32473/v1 Date: 2020-05-29 Source: ResearchSquare

    The novel Coronavirus 19 infection spread rapidly from Wuhan, Hubei Province – China, to the worldwide, becoming a pandemic. The infection does not cause only flu-like syndrome MESHD ( fever HP fever MESHD, dry cough and shortness of breath MESHD) and respiratory distress HP of varying severity but also affects the kidneys, the heart, the nervous system and the circulatory apparatus, causing thromboembolic MESHD events. Usually these problems occur in patients with severe respiratory failure HP respiratory failure MESHD admitted to Intensive Care Unit and with pre-existing comorbidities.We report the case of a patient without Covid symptoms who had thrombotic stroke MESHD stroke HP as the presenting features of Coronavirus infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.